Boyd H K, Lappin T R
Department of Haematology, Royal Victoria Hospital, N. Ireland.
Eur J Haematol. 1991 Apr;46(4):198-201. doi: 10.1111/j.1600-0609.1991.tb00540.x.
Defective iron metabolism, mild haemolysis and impaired erythropoiesis contribute to the anaemia of chronic disorders (ACD), but evidence for a deficiency of circulating erythropoietin (Epo) is equivocal. We have examined serum Epo in moderately anaemic patients with Hb less than 10 g/dl--41 patients with ACD (23 associated with rheumatoid disease and 18 with malignancy), 17 with uncomplicated iron-deficiency anaemia and 33 with chronic renal failure (CRF). In ACD the serum Epo (mean (confidence limits] results of 41 (31, 54) mU/ml for the rheumatoid group and 63 (49, 80) mU/ml for the malignancy group, were significantly lower than the Epo of 104 (78, 136) mU/ml for the iron-deficiency group. The CRF group with more severe anaemia had serum Epo of 27 (19, 35) mU/ml. Thus, recombinant human erythropoietin (rHu Epo) should be considered for the treatment of ACD associated with rheumatoid disease and malignancy.
铁代谢缺陷、轻度溶血和红细胞生成受损导致慢性病性贫血（ACD），但循环促红细胞生成素（Epo）缺乏的证据并不明确。我们检测了血红蛋白低于10 g/dl的中度贫血患者的血清Epo——41例ACD患者（23例与类风湿病相关，18例与恶性肿瘤相关）、17例单纯缺铁性贫血患者和33例慢性肾衰竭（CRF）患者。在ACD患者中，类风湿病组血清Epo平均（置信区间）结果为41（31, 54）mU/ml，恶性肿瘤组为63（49, 80）mU/ml，均显著低于缺铁性贫血组的104（78, 136）mU/ml。贫血更严重的CRF组血清Epo为27（19, 35）mU/ml。因此，对于与类风湿病和恶性肿瘤相关的ACD，应考虑使用重组人促红细胞生成素（rHu Epo）进行治疗。
